![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
1 Adrenergic Receptor-Mediated Enhancement of Hippocampal CA3 Network Activity
Department of Pharmacology, Physiology, and Therapeutics (C.W.D.J., K.E.R., J.D.K., J.E.P., V.A.D.) and Department of Anatomy and Cell Biology (C.A.K., P.A.C.), University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota
Received February 23, 2005; accepted May 17, 2005.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
adrenergic receptor (AR) activation, has been shown to reinforce the cognitive processes of attention and memory. In this study, we investigated the effect of 1AR activation on hippocampal cornu ammonis 3 (CA3) network activity. AR expression was first determined using immunocytochemistry with antibodies against 1ARs, which were found to be exceptionally dense in hippocampal CA3 pyramidal neurons. CA3 network activity was then examined in vitro using field potential recordings in rat brain slices. The selective AR agonist isoproterenol caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region. In the presence of 
AR blockade, concentration-response curves for isoproterenol, norepinephrine, and epinephrine suggested that a 1AR was involved in this response, and the rank order of potency was isoproterenol > norepinephrine = epinephrine. Finally, equilibrium dissociation constants (pKb) of subtype-selective AR antagonists were functionally determined to characterize the AR subtype modulating hippocampal CA3 activity. The selective 1AR antagonists atenolol and metoprolol blocked isoproterenol-induced enhancement, with apparent Kb values of 85 ± 36 and 3.9 ± 1.7 nM, respectively. In contrast, the selective 2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (Kb of 222 ± 61 and 9268 ± 512 nM, respectively). Together, this pharmacological profile of subtype-selective AR antagonists indicates that in this model, 1AR activation is responsible for the enhanced hippocampal CA3 network activity initiated by isoproterenol.
). Due to this rich and widespread projection of adrenergic axons, it is thought that the neurotransmitter NE plays a modulatory role in some global aspects of brain function. Indeed, the adrenergic system is shown to be involved in a variety of CNS functions, including regulating the sleep-wake cycle (Berridge and Waterhouse, 2003), modulating electroencephalographic activity (Foote et al., 1983), promoting a state of vigilance (Aston-Jones and Bloom, 1981), thermoregulation (Philipson, 2002), and enhancing learning and memory (Kobayashi and Kobayashi, 2001).
Among the many targets of NE-containing axons in the brain is the hippocampus (Jones and Moore, 1977; Loy et al., 1980), which receives one of the highest densities of adrenergic terminals in the CNS (Schroeter et al., 2000). The hippocampus occupies a central position in the neural circuits that govern emotions, motivation, attention, and certain types of memory processes (Milner et al., 1998; Eichenbaum, 2000). The hippocampus also has a pathological role in Alzheimer's disease (Hyman et al., 1984; Braak and Braak, 1997) and schizophrenia (Luchins, 1990), has been shown to be exceptionally vulnerable to ischemia and anoxia (Tekkok and Ransom, 2004), and is of particular interest in epilepsy due to its low seizure threshold and frequent involvement in hyperexcitable episodes (Johnston and Amaral, 2004). The hippocampus is also the site where a form of activity-dependent synaptic enhancement, called long-term potentiation (LTP), was first shown. This potentiation of excitatory activity may be the cellular basis of learning and memory (Bliss and Collingridge, 1993).
Specificity in the adrenergic system is believed to be achieved primarily through a distinct and diverse expression pattern of postsynaptic adrenergic receptors (ARs). Activation of these ARs is often seen to produce state-dependent or enabling effects, with different receptor subtypes often mediating opposing effects within a cell. Pharmacological and molecular cloning studies have revealed the existence of three AR subtypes (1, 2, and 3), based upon both sequence homologies and affinity values for subtype-selective AR antagonists. Although all ARs are positively coupled to adenylyl cyclase via activation of the G protein Gs, each subtype has its own unique pharmacological characteristics, particularly for catecholamine AR agonists (Pupo and Minneman, 2001). For example, the relative potencies of isoproterenol (ISO), NE, and epinephrine (EPI) differ at each receptor subtype: ISO > NE 
EPI for 1; ISO > EPI > NE for 2; and ISO > NE > EPI for 3AR (Lands et al., 1967; Emorine et al., 1989; Bylund et al., 1994). In addition, ISO is essentially equipotent at 1 and 2AR subtypes, whereas it is considerably less potent for the 3AR (Liggett, 1992; Galitzky et al., 1995; Shimizu et al., 1996). Although much is known about the role of AR subtypes in the periphery, far less is known about their function in the CNS.
All three AR subtypes are found in the brain, albeit the 3AR subtype seems to have a very limited expression pattern (Pupo and Minneman, 2001). In the hippocampus, AR activation has been shown to facilitate LTP (Hopkins and Johnston, 1984; Gelinas and Nguyen, 2005) as well as to enhance certain memory processes (Murchison et al., 2004). Delineating which subtype of AR mediates specific physiological functions in the hippocampus would help clarify a role for the AR system in cognitive function.
The goal of this study was to characterize the effect of AR subtype activation on hippocampal cornu ammonis 3 (CA3) network synchronization in the rat hippocampus. Immunohistochemical staining and rank order of potencies for catecholamine-mediated responses suggested that activation of a 1AR population was increasing synchronous burst activity in the CA3 region. Functional determination of subtype-selective AR antagonist affinity values were used to support this assumption. Kb values calculated using Schild regression analysis confirmed our hypothesis that 1AR activation is responsible for the enhanced hippocampal CA3 network activity observed in this model of adrenergic transmission.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Animals. Sprague-Dawley rats, postnatal day 12 to 29 (P12–29) were housed with their mothers in cages (16.5 x 8.5 inches) kept in rooms maintained at a temperature of 
22°C with a relative humidity of 55%. Water and dried laboratory food (Teklad Global 18% Protein Rodent Diet; Harlan Teklad, Madison, WI) were provided ad libitum. Lighting was set to a 12-h light/dark cycle (lights on at 7:00 AM). Rats were allowed to acclimate for 4 days after arrival from Harlan (Indianapolis, IN) before their use. All protocols described were approved by the Institutional Animal Care and Use Committee of the University of North Dakota in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Immunocytochemistry. Five Sprague-Dawley rats (P20–21; 50–70 g) were anesthetized with pentobarbital and perfused transcardially with 100 ml of ice-cold (4°C) 0.9% saline containing 0.1% sodium nitrite followed by 400 ml of ice-cold, freshly prepared fixative consisting of 4% paraformaldehyde and 0.16% para-picric acid in 0.1 M sodium phosphate buffer, pH 7.4. The brain was removed immediately after perfusion and postfixed for 2 h in ice-cold fixative followed by cryoprotection for at least 48 h in ice-cold (4°C) 25% sucrose and 10% glycerol in 50 mM phosphate buffer. Sagittal sections of brain (20 µm in thickness) were cut on a freezing sliding microtome (Leica 3000R) and collected into 0.1 M sodium phosphate buffer, pH 7.4, containing 0.9% saline (phosphate-buffered saline) and processed for immunohistochemistry as described below.
Whole brain sections were incubated for 48 to 72 h at 4°C with anti-1AR (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-calmodulin kinase-II (CaMK-II; Chemicon International, Temecula, CA) primary antibodies alone or simultaneously. CaMK-II is a marker of pyramidal neurons. All primary antibodies were diluted 1:200 in phosphate-buffered saline containing 0.3% Triton X-100 (PBS-T). After the primary incubation, the sections were washed in two 20-min washes in PBS-T and then incubated for 1.5 h at room temperature with CY3-conjugated donkey anti-rabbit or donkey anti-mouse IgG secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:100 in PBS-T. Sections were then washed for 20 min in PBS-T, 20 min in 50 mM Tris-HCl, and mounted onto gel-coated slides using 50 mM Tris-HCl, pH 7.4. Slides were coverslipped with Vectashield (Vector Laboratories, Burlingame, CA) antifade mounting medium. For double-immunofluorescence labeling, anti-1AR and anti-CaMK-II primary antibody labeling was visualized using CY3-conjugated donkey anti-rabbit IgG and fluorescein isothiocyanate-conjugated donkey anti-rabbit IgG secondary antibodies (both 1:100; Jackson ImmunoResearch Laboratories). Immunohistochemical controls consisted of primary omission for both single and double immunohistochemistry labeling. Analysis of immunoreactivity and determination of labeling colocalization were undertaken using standard fluorescence microscopy (BX-60; Olympus, Melville, NY) and image analysis (Spot RT slider; ImagePro, Sterling Heights, MI).
Slice Preparation. Hippocampal brain slices were prepared from Sprague-Dawley rats (P12–29; 25–90 g) as follows. Briefly, animals were deeply anesthetized with isoflurane, sacrificed by decapitation, and their brains were rapidly removed. Hippocampi were dissected from each hemisphere and placed into a beaker of ice-cold saline solution containing 110 mM choline chloride, 2.5 mM KCl, 7 mM MgSO4, 0.5 mM CaCl2, 1.25 mM NaH2PO4, 25 mM NaHCO3, 25 mM glucose, 11.6 mM sodium ascorbate, and 3.1 mM sodium pyruvate. The hippocampi were sectioned transversely into 500-µm-thick slices using a conventional tissue sectioning apparatus (Stoelting, Wood Dale, IL). The hippocampal slices were incubated at 34 ± 1°C in ACSF containing in 119 mM NaCl, 5 mM KCl, 1.3 mM MgSO4, 2.5 mM CaCl2, 1 mM NaH2PO4, 26.2 mM NaHCO3, and 11 mM glucose, for 30 min before being allowed to recover for at least an additional 30 min at room temperature (22 ± 1°C). All solutions were continually aerated with 95% O2, 5% CO2.
|
It has been established that hippocampal CA3 pyramidal neurons will fire burst discharges due in part to extensive recurrent circuitry (Traub et al., 1991). This activity can be elicited by attenuating synaptic inhibition using a GABAA receptor antagonist such as picrotoxin. Since this particular characteristic is present exclusively in CA3 pyramidal cells, the frequency of burst discharges can serve as a selective measure of hippocampal CA3 neural network activity.
All experiments were performed at room temperature (22 ± 1°C). Slices were continually superfused with ACSF containing picrotoxin at 100 µM (to elicit burst discharges) and any applicable receptor antagonists. If no burst discharges were seen after 20 min of perfusion, the slices were determined to be unresponsive and discarded. Once burst discharges were evident, 30 min of baseline data was recorded before any exposure to agonist. Preliminary experiments were conducted to ensure that pharmacological antagonists showed no effect on their own and that each agonist dose produced its maximum effect in the time allotted (data not shown).
Data Analysis. Burst discharge frequency was analyzed using Mini Analysis 6.0 (Synaptosoft, Decatur, GA). Frequency versus agonist concentration data were then entered into GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA), and concentration-response curves were constructed using a nonlinear least-squares curve-fitting method. Concentration-response curves for an agonist were plotted as percentage of maximal response. Each curve was fit with a standard (slope = unity) or variable slope, and the best fit was determined using an F-test with a value of P < 0.05. The calculated EC50 value was used as a measurement of agonist potency. Significance between groups was tested using an unpaired two-tailed Student's t test (P < 0.05).
Schild analysis was used to functionally determine apparent equilibrium dissociation constants (pKb) for atenolol, butoxamine, ICI-118,551, and metroprolol (Arunlakshana and Schild, 1959). For each experiment, cumulative concentration-response curves were performed in adjacent hippocampal slices of the same rat (one concentration-response curve per slice). Dose ratios of EC50 values in the presence and absence of a selective AR antagonist were calculated and Schild plots constructed by graphing the log of the dose ratio – 1 versus the log of the concentration of that AR antagonist (Arunlakshana and Schild, 1959). Linear regression analysis of these plotted points was used to determine the slope and x-intercept of the Schild regressions. Schild regression slopes are expressed as the mean ± 95% confidence interval and were only considered different from unity if the 95% confidence interval did not include the value of 1 (Kenakin, 1997). The pKb values of subtype-selective AR antagonists causing competitive inhibition of agonist initiated burst discharge frequencies were calculated from Schild regression x-intercepts. Differences in pKb values and Schild regression slopes were determined by analysis of covariance with a P < 0.05 level of probability accepted as significant. Calculated values (i.e., EC50 and Kb) are expressed as the mean ± S.E.M. for n experiments.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
1AR Distribution in the Rat Hippocampal Formation. Sagittal sections of p21 rat whole brain displayed abundant and intense 1AR and CaMK-II immunolabeling in the hippocampus. 1AR immunofluorescent puncta were observed along the plasma membrane of both the perikarya and proximal dendrites of putative pyramidal cells in the hippocampal CA3 region (Fig. 1, A and B). Compared with the perikarya, dendrites displayed a lower concentration of 1AR immunofluorescent labeling. As a control, a similar intense 1AR immunofluorescent labeling was observed in fixed sections of the rat heart (Fig. 1A, inset), and alternatively, minimal 1AR labeling was documented in tissue preparations from the rat lung (data not shown). Within the hippocampus, 1AR immunoreactivity was observed on pyramidal cells in all three cytoarchitectural regions, with cells in the CA3 displaying the heaviest labeling (Fig. 1A). CaMK-II immunofluorescence was also observed within pyramidal cells of the stratum pyramidale in the same cytoarchitectural regions of the hippocampus. This labeling was localized within both perikarya and proximal processes (Fig. 1C). These CaMK-II results reflect those reported previously and confirm the utility of CaMK-II as a marker of pyramidal cells in the hippocampus (Goto et al., 1993). In tissue double labeled for CaMK-II and 1AR, CaMK-II-labeled pyramidal cells in the CA3 also displayed intense and abundant somatic and dendritic 1AR immunofluorescent puncta (Fig. 1D). These results suggest that there is a distinct pattern of 1AR expression located predominantly on the hippocampal CA3 pyramidal neurons. These data, however, do not give an indication as to the role this AR subtype may be performing with respect to hippocampal network activity.
|
AR Effects on Hippocampal CA3 Network Activity. To determine possible AR action on hippocampal activity, we examined the effects of AR agonists on burst discharges recorded extracellularly from the hippocampal CA3 pyramidal cell layer. For these recordings, the electrode was placed precisely in the area of the CA3 region that showed the greatest intensity of 1AR and CaMK-II immunofluorescence (Fig. 2). As illustrated in Fig. 2A, picrotoxin-induced burst discharges seen as sharp biphasic spikes. The depolarizing/hyperpolarizing waveform corresponds to a series of population spikes followed by an afterhyperpolarization in CA3 pyramidal neurons (Traub et al., 1991). Application of the selective AR agonist ISO caused a concentration-dependent increase in the number of these events (Fig. 2). Using a frequency histogram of the ISO-induced increase in burst discharges (Fig. 2B), a concentration-response curve can be constructed from a plot of maximal burst frequency versus ISO concentration (Fig. 2B, inset). For this experiment, the EC50 value calculated from nonlinear regression analysis was 13.7 nM. Overall, the mean EC50 value for ISO-induced increased burst firing was 13.6 ± 1.3 nM (n = 14) (Fig. 2C), suggesting that ISO initiates an enhancement of hippocampal CA3 network activity most likely through AR activation.
Effects of Endogenous Catecholamines on Hippocampal CA3 Network Activity. Since NE and EPI are the endogenous agonists for AR-mediated responses in the rat hippocampus, we compared the effects of these nonselective AR agonists to ISO on hippocampal CA3 burst activity frequency in the presence of AR blockade. After pretreatment of slices with 10 µM phentolamine, application of ISO, NE, or EPI again caused a concentration-dependent increase in the frequency of hippocampal burst discharges (Fig. 3). The potency of ISO in the presence of phentolamine (14.4 ± 1.8 nM; n = 5) was not significantly different from ISO EC50 values calculated in the absence of AR blockage (13.6 ± 1.3 nM; n = 14). This illustrates that the ISO-mediated effects on the hippocampus are caused by selective AR activation and not due to a nonspecific AR response. Conversely, the EC50 of NE (307 ± 64 nM; n = 5) and EPI (231 ± 21 nM; n = 5) for increasing CA3 network activity were similar compared with each other but were significantly less potent when evaluated against ISO. This rank order of potency (ISO > NE = EPI) is consistent with results by others who historically characterized catecholamine-initiated responses caused by 1AR activation (Lands et al., 1967). As expected for full AR agonists, there were no significant differences between the maximal effects produced by NE, EPI, or ISO (data not shown).
|
1AR Competitive Antagonists on the ISO-Mediated Increase in Discharge Frequencies. Functional determination of subtype-selective AR antagonist affinity values were used to characterize the AR subtype mediating increased burst frequency in the hippocampal CA3 region. Initially, CA3 field potential recordings generated by increasing amounts of ISO in the absence and presence of fixed selective 1AR antagonist concentrations were used for Schild regression analysis (Fig. 4). Hippocampal slices that had been pretreated with 200, 500, 1000, and 2000 nM atenolol produced 4-, 8-, 16-, and 30-fold parallel rightward shifts of the fitted ISO concentration-response curve (Fig. 4A). Dose ratios calculated for individual runs were plotted against each atenolol concentration to generate a straight line using linear regression analysis (Fig. 4B). The Schild regression slope included the value of unity (1.1 ± 0.5), and the x-intercept of the regression line represents the atenolol equilibrium dissociation constant (pKb) for the AR subtype mediating the increased burst frequency. The apparent Kb of 85 ± 36 nM correlates to previously published value where atenolol was used to identify the 1AR subtype (Table 1).
|
|
Similar experiments using 10, 30, 100, and 300 nM of metoprolol again produced 3-, 6-, 26-, and 56-fold parallel rightward shifts of the fitted ISO concentration-response curve (Fig. 4C). The Schild regression slope for metoprolol (Fig. 4D) included the value of unity (1.0 ± 0.2) and the calculated apparent Kb (3.9 ± 1.7 nM) correlates to published values of metoprolol for the 1AR subtype (Table 1). The high-affinity values calculated for these subtype-selective AR antagonists to inhibit ISO initiated burst activity suggests that 1AR activation is the specific AR mediating this response in the hippocampal CA3 region.
Effect of Selective 2AR Competitive Antagonists on the ISO-Mediated Increase in Discharge Frequencies. Apparent affinity values of selective 2AR competitive antagonists ICI-118,551 and butoxamine were also calculated to corroborate results obtained using selective 1AR competitive antagonists. In these experiments, hippocampal slices pretreated with 500, 1000, 3000, and 10,000 nM ICI-118,551 produced 3-, 5-, 9-, and 27-fold parallel rightward shifts of the fitted ISO concentration-response curve (Fig. 5A). Dose ratios calculated for each ICI-118,551 concentration were used for Schild regression analysis (Fig. 5B). The slope of the regression line included the value of unity (0.9 ± 0.2), and the apparent Kb of 222 ± 61 nM correlates to previously published values where ICI-118,551 was used to identify the 1AR subtype (Table 1).
|
1AR subtype (Table 1). The low-affinity values calculated for these selective 2AR antagonists to inhibit ISO initiated burst activity indicates that 1AR activation is the specific AR mediating this CA3 response.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
AR subtype-mediated enhancement of hippocampal CA3 network activity. Previous studies have suggested 1AR activation may mediate powerful excitatory actions on pyramidal cells in the hippocampus. Therefore, we first investigated an anatomical basis for this excitatory action by examining the abundance and distribution of immunohistochemically localized 1AR on the somatic and dendritic plasma membrane of CaMK-II-identified pyramidal cells (Goto et al., 1993). 1AR labeling was present on the perikarya and proximal dendrites of pyramidal cells in all three cytoarchitectural regions in the rat hippocampus. The heaviest labeling was observed along the plasma membrane and within the cytoplasm of cells within the CA3 region. Less abundant 1AR labeling was observed in the CA1 pyramidal cell layer compared with CA3, which is indicative of a distinct pattern for AR subtype expression. This observation is supported by molecular and functional studies that show a lack of 1AR expression and functionality from CA1 pyramidal cells (Hillman et al., 2005a,b). This distinct and diverse AR subtype expression pattern would provide a means for AR signaling specificity in the hippocampus.
Before introduction of subtype-specific AR antagonists, AR subtypes were traditionally identified using a profile of AR agonists (Lands et al., 1967). In the present study, application of the selective AR agonist ISO or the nonselective AR agonists, NE or EPI, in the presence of AR blockade caused a concentration-dependent increase in the frequency of hippocampal CA3 burst discharges. For this response, ISO was found to have the highest potency of these tested AR agonists, whereas NE was equipotent to EPI. The high potency of ISO to initiate an increased CA3 burst discharge implies that 3AR activation is not mediating this function (Hoffmann et al., 2004). Furthermore, a rank order of potency demonstrating ISO > NE = EPI implies that the 1AR population identified from immunohistochemical analysis may be responsible for this hippocampal CA3 hyperexcitability (Lands et al., 1967; Bylund et al., 1994).
Additional support of our hypothesis for a 1AR mediation of hippocampal CA3 hyperexcitability comes from functional determination of subtype-selective AR antagonist affinity values using the method of Arunlakshana and Schild (1959). Increasing concentrations of all AR antagonists used in this study caused parallel rightward shifts in the ISO concentration-response curves without significantly reducing maximal effects, demonstrating the competitive property of these receptor antagonists. Low apparent equilibrium dissociation constants calculated for the selective 1AR antagonists atenolol and metoprolol support our belief that 1AR activation enhances CA3 network activity. Moreover, high apparent Kb values determined for the selective 2AR antagonists ICI-118,551 and butoxamine maintain our assertion that activated 1AR subtypes are mediating this hippocampal CA3 response. The pharmacological profile in our studies is comparable with the Ki values of these subtype-selective AR antagonists for 1ARs as determined by others using radio-ligand binding studies (Quast and Vollmer, 1984; Juberg et al., 1985). In addition, the rank order of affinity values for these subtype-selective AR antagonists (metroprolol > atenolol » ICI-118,551 > butoxamine) is consistent with the characteristics for a 1AR subtype described in other investigations (Table 1). Together, these results indicate that ISO activation of 1AR subtypes is mediating the increased network activity in the CA3 hippocampus.
Until recently, little was known about the role of hippocampal CA3 activity in the cognitive functions of attention and memory, except that LTP had been demonstrated at the recurrent collateral-CA3 synapses. However, recent evidence indicates that the CA3 pyramidal neurons, which mediate network activity, play a crucial role in associative memory recall (Nakazawa et al., 2002) and rapid memory acquisition (Nakazawa et al., 2003). Furthermore, new in vivo studies with mutant mice lacking NE has confirmed a role for NE in memory retrieval (Murchison et al., 2004). Moreover, selective use of AR agents also suggested that this NE function required signaling through a hippocampal 1AR subtype. Since AR activation has been previously shown to decrease calcium-activated potassium conductance by a cAMP-dependent mechanism (Madison and Nicoll, 1986a,b), we speculate that 1AR activation enhances hippocampal CA3 network activity by increasing glutamatergic neurotransmission between recurrent collaterals of pyramidal cells, most likely by decreasing calcium-activated potassium conductance in a cAMP-dependent manner. Additional experiments are currently being performed to confirm this hypothesis.
In conclusion, we provide functional evidence that 1AR activation increases hippocampal CA3 burst activity. We hypothesize that this 1AR-mediated enhancement of CA3 network activity could be the underlying mechanism through which NE reinforces certain cognitive processes such as memory retrieval in the hippocampus.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: CNS, central nervous system; NE, norepinephrine; LTP, long-term potentiation; AR, adrenergic receptor; ISO, isoproterenol; EPI, epinephrine; ICI-118,551, (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl) amino]-2-butanol; CA3, cornu ammonis 3; ACSF, artificial cerebrospinal fluid; P, postnatal; PBS-T, phosphate-buffered saline containing 0.3% Triton X-100; CaMK-II, calmodulin kinase-II.
1 These authors contributed equally to this work. 
Address correspondence to: Dr. Van A. Doze, Department of Pharmacology, Physiology and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, 501 North Columbia Rd., Grand Forks, ND 58202-9037. E-mail address: vdoze{at}medicine.nodak.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48–58.[Medline]
Aston-Jones G and Bloom FE (1981) Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1: 887–900.[Abstract]
Berridge CW and Waterhouse BD (2003) The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42: 33–84.[CrossRef][Medline]
Bliss TV and Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature (Lond) 361: 31–39.[CrossRef][Medline]
Braak H and Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351–357.[CrossRef][Medline]
Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, and Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121–136.[Medline]
Eichenbaum H (2000) A cortical-hippocampal system for declarative memory. Nat Rev Neurosci 1: 41–50.[CrossRef][Medline]
Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, and Strosberg AD (1989) Molecular characterization of the human 3-adrenergic receptor. Science (Wash DC) 245: 1118–1121.
Foote SL, Bloom FE, and Aston-Jones G (1983) Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63: 844–914.
Galitzky J, Carpene C, Bousquet-Melou A, Berlan M, and Lafontan M (1995) Differential activation of 1-, 2- and 3-adrenoceptors by catecholamines in white and brown adipocytes. Fundam Clin Pharmacol 9: 324–331.[Medline]
Gelinas JN and Nguyen PV (2005) -Adrenergic receptor activation facilitates induction of a protein synthesis-dependent late phase of long-term potentiation. J Neurosci 25: 3294–3303.
Goto S, Nagahiro S, Korematsu K, Ushio Y, Fukunaga K, Miyamoto E, and Hofer W (1993) Cellular colocalization of calcium/calmodulin-dependent protein kinase II and calcineurin in the rat cerebral cortex and hippocampus. Neurosci Lett 149: 189–192.[CrossRef][Medline]
Hillman KL, Doze VA, and Porter JE (2005a) Functional characterization of the -adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus. J Pharmacol Exp Ther 314: 561–567
Hillman KL, Knudson CA, Carr PA, Doze VA, and Porter JE (2005b) Adrenergic receptor characterization of CA1 hippocampal neurons using real time, single cell RT-PCR. Brain Res Mol Brain Res, in press.
Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, and Klotz KN (2004) Comparative pharmacology of human -adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369: 151–159.[Medline]
Hopkins WF and Johnston D (1984) Frequency-dependent noradrenergic modulation of long-term potentiation in the hippocampus. Science (Wash DC) 226: 350–352.
Hyman BT, Van Hoesen GW, Damasio AR, and Bernes CL (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (Wash DC) 225: 1168–1171.
Johnston B and Amaral DG (2004) Hippocampus, in The Synaptic Organization of the Brain (Shepherd GM ed) pp 455–498, Oxford University Press, New York.
Jones BE and Moore RY (1977) Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. Brain Res 127: 25–53.[Medline]
Juberg EN, Minneman KP, and Abel PW (1985) Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 330: 193–202.[CrossRef][Medline]
Kenakin T (1997) Competitive antagonism, in Pharmacologic Analysis of Drug-Receptor Interaction (Kenakin T ed) 3rd ed, pp 331–373, Lippincott-Raven, Philadelphia.
Kobayashi K and Kobayashi T (2001) Genetic evidence for noradrenergic control of long-term memory consolidation. Brain Dev 23: S16–S23.
Lands AM, Arnold A, McAuliff JP, Luduena FP, and Brown TG Jr (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature (Lond) 214: 597–598.[CrossRef][Medline]
Liggett SB (1992) Functional properties of the rat and human 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42: 634–637.[Abstract]
Loy R, Koziell DA, Lindsey JD, and Moore RY (1980) Noradrenergic innervation of the adult rat hippocampal formation. J Comp Neurol 189: 699–710.[CrossRef][Medline]
Luchins DJ (1990) A possible role of hippocampal dysfunction in schizophrenic symptomatology. Biol Psychiatry 28: 87–91.[CrossRef][Medline]
Madison DV and Nicoll RA (1986a) Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol (Lond) 372: 221–244.
Madison DV and Nicoll RA (1986b) Cyclic adenosine 3',5'-monophosphate mediates -receptor actions of noradrenaline in rat hippocampal pyramidal cells. J Physiol (Lond) 372: 245–259.
Milner B, Squire LR, and Kandel ER (1998) Cognitive neuroscience and the study of memory. Neuron 20: 445–468.[CrossRef][Medline]
Moore RY and Bloom FE (1979) Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine. Annu Rev Neurosci 2: 113–168.[CrossRef][Medline]
Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, and Thomas SA (2004) A distinct role for norepinephrine in memory retrieval. Cell 117: 131–143.[CrossRef][Medline]
Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, Kato A, Carr CA, Johnston D, Wilson MA, et al. (2002) Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science (Wash DC) 297: 211–218.
Nakazawa K, Sun LD, Quirk MC, Rondi-Reig L, Wilson MA, and Tonegawa S (2003) Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience. Neuron 38: 305–315.[CrossRef][Medline]
Philipson LH (2002) -Agonists and metabolism. J Allergy Clin Immunol 110: S313–S317.[CrossRef][Medline]
Pupo AS and Minneman KP (2001) Adrenergic pharmacology: focus on the central nervous system. CNS Spectr 6: 656–662.[Medline]
Quast U and Vollmer KO (1984) Binding of -adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung 34: 579–584.[Medline]
Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, and Blakely RD (2000) Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 420: 211–232.[CrossRef][Medline]
Shimizu M, Blaak EE, Lonnqvist F, Gafvels ME, and Arner P (1996) Agonist and antagonist properties of 3-adrenoceptors in human omental and mouse 3T3–L1 adipocytes. Pharmacol Toxicol 78: 254–263.[Medline]
Tekkok SB and Ransom BR (2004) Anoxia effects on CNS function and survival: regional differences. Neurochem Res 29: 2163–2169.[CrossRef][Medline]
Traub RD, Wong RK, Miles R, and Michelson H (1991) A model of a CA3 hippocampal pyramidal neuron incorporating voltage-clamp data on intrinsic conductances. J Neurophysiol 66: 635–650.
Tsuchihashi H, Nakashima Y, Kinami J, and Nagatomo T (1990) Characteristics of 125I-iodocyanopindolol binding to -adrenergic and serotonin-1B receptors of rat brain: selectivity of -adrenergic agents. Jpn J Pharmacol 52: 195–200.[Medline]
This article has been cited by other articles:
|
|
 |
|
  K. L. Hillman, V. A. Doze, and J. E. Porter Functional Characterization of the {beta}-Adrenergic Receptor Subtypes Expressed by CA1 Pyramidal Cells in the Rat Hippocampus J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 561 - 567. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
), NE (
), or EPI (
) in the presence of 10 µM phentolamine. There was a significant difference in the potencies calculated for NE (307 ± 64 nM) or EPI (231 ± 21 nM) compared with ISO (14.4 ± 1.8 nM). However, there were no significant differences between the EC50 calculated for NE and EPI. Concentration-response curves for each agonist were plotted as percent of maximal response (increase in burst frequency). Each individual experiment best fit to a nonvariable sigmoidal curve (n = 5).
), 1000 (
) of this AR antagonist produced consecutive parallel rightward shifts of the ISO curve that were significantly different from control (